The global DNA gyrase subunit B (EC 5.99.1.3) market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). DNA gyrase is an essential bacterial enzyme that belongs to the topoisomerases class of enzymes that controls the topological transitions of DNA. Additionally, it catalyzes the ATP-dependent negative super-coiling of double-stranded closed-circular DNA. The major factor accelerating the growth of the market is the increasing prevalence of bacterial infections across the globe.

Moreover, based on application, the market is segmented into bacterial infections, clostridium diffclie infections, klebsiella pneumoniae infections, and others. Clostridium diffclie infections are anticipated to hold a major share in the market due to the rising incidence rate. According to the National Center for Biotechnology Information (NCBI), in 2017, there was an estimated 235,700 cases with an estimated incidence rate of 73.3 per 100,000 population in the US.

Some major players in the market include Bristol-Myers Squibb Co., AstraZeneca Plc, and Merck & Co., Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in October 2019, GlaxoSmithKline Plc announced the beginning of patient dosing in a phase III clinical programme investigating gepotidacin. Gepotidacin is a new chemical class of antibiotics called triazaacenaphthylene bacterial topoisomerase inhibitors used for the treatment of patients with uncomplicated urinary tract infection and urogenital gonorrhoea (GC). The drug works by interacting with two key bacterial enzymes, DNA gyrase and topoisomerase IV

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape- Bristol-Myers Squibb Co., AstraZeneca Plc, and Merck & Co., Inc., among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Report by Segment

By Type 

    • GYR-12

    • DS-2969

    • VXC-100

    • VT-12008911

    • Others

By Application

    • Bacterial Infections

    • Clostridium Diffclie Infections 

    • Klebsiella Pneumoniae Infections 

    • Others

Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Report by Region

North America

    • United States

    • Canada

Europe

    • UK

    • Germany

    • Italy

    • Spain

    • France

    • Rest of Europe 

Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Rest of Asia-Pacific 

Rest of the World

    • Latin America 

    • Middle East & Africa